Endo Launches BELBUCA Buccal Film For Chronic Pain Management

(RTTNews) - Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP, ENL.TO), announced the availability of BELBUCA (buprenorphine) buccal film, the first and only buprenorphine formulation developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. BELBUCA, distributed and promoted by Endo, is now available nationwide.

BELBUCA is available in seven dosage strengths for flexible dosing from 75 µg to 900 µg every 12 hours, allowing physicians to titrate BELBUCA™ individually for patients to a tolerable dose that provides adequate analgesia with minimal side effects.

BELBUCA (buprenorphine) buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.